Skip to content

Journal · Cancer research · Updated 20 November 2026

Nature Cancer

Read Nature Cancer articles on DeepDyve. No university library needed.

Nature Cancer has published since 2020 and covers cancer research from tumor biology and immunology to clinical trials, including work on immunotherapy, metastasis and AI for cancer screening. It is part of Springer Nature’s Nature Portfolio. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Nature Cancer
November 2026 issue

Nature Cancer at a glance

Full title
Nature Cancer
Abbreviation (NLM)
Nat Cancer
Publisher
Springer Nature (Nature Portfolio)
ISSN (online only)
2662-1347
First published
2020
Subjects
Neoplasms
Access model
Hybrid (26% free to read in 2026)

Ways to access Nature Cancer

26% of the articles Nature Cancer published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for a preprint or the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 26% of Nature Cancer articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. Preprints. Nature Cancer encourages authors to post preprints of their research on servers such as arXiv or bioRxiv. A preprint can differ from the published paper.
  3. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Nature Cancer. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Nature Cancer articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; Nature Portfolio preprint policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Nature Cancer’s 2025 Journal Impact Factor is 28.0, and its 5-year Impact Factor is 31.2.

28.0

Journal Impact Factor (2025)

31.2

5-year Impact Factor (2025)

12.443

SCImago Journal Rank (2025)

8 days

Median time to first editorial decision

242 days

Median time from submission to acceptance

26%

Articles published open access, Jan 1 to Nov 19, 2026

Source: Springer Nature journal metrics for Nature Cancer. Impact Factor from Clarivate Journal Citation Reports. Open access share: 45 of 172 articles published January 1 to November 19, 2026 carry a Creative Commons license, per Crossref.

Recent Nature Cancer research worth reading

Published January to April 2026. Summaries describe what the authors report.

  1. Open accessHead and neck cancer · Immunotherapy

    Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma

    Analyzing oropharyngeal head and neck cancers from the CIAO trial, Silver and colleagues report that the total abundance of intratumoral bacteria predicted response to checkpoint blockade, and that raising it in mouse models was enough to induce resistance to anti-PDL1 treatment.

    Silver et al. · Nature Cancer, published online January 2, 2026 · DOI 10.1038/s43018-025-01067-1

  2. LitStreamGlioblastoma · Tumour immunology

    Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity

    Moreno-Sanchez and colleagues discuss how innate and adaptive immune cells together build an immunosuppressive microenvironment that supports glioblastoma growth and resistance to treatment, and introduce local priming and rewiring of that environment as foundations for more durable responses.

    Moreno-Sanchez et al. · Nature Cancer, published online January 8, 2026 · DOI 10.1038/s43018-025-01097-9

  3. LitStreamSpatial omics · Tumour microenvironment

    Cellular neighborhoods in cancer

    In this Perspective, Ma and colleagues bring together emerging ideas on cellular neighborhoods, recurring tissue structures with characteristic cell makeup, covering how to define and classify them in cancer, computational methods to find and compare them, and their clinical relevance.

    Ma et al. · Nature Cancer, published online January 16, 2026 · DOI 10.1038/s43018-025-01107-w

  4. LitStreamTumour microenvironment · Fibroblasts

    Heterogeneity and plasticity of cancer-associated fibroblasts

    Pramod and colleagues review current understanding of cancer-associated fibroblasts as varied, instructive regulators of tumour microenvironments across body sites, drawing on single-cell and spatial studies of distinct fibroblast states, and highlight key challenges for future work.

    Pramod et al. · Nature Cancer, published online April 20, 2026 · DOI 10.1038/s43018-026-01146-x

  5. LitStreamCAR T cell therapy · Solid tumours

    Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial

    In a phase 1 trial of the CAR T cell therapy PC13 in 43 heavily pretreated people with CEA-positive solid tumours, Gao and colleagues report disease control rates of 82.4% with intraperitoneal and 68.0% with intravenous infusion, and manageable toxicity.

    Gao et al. · Nature Cancer, published online February 27, 2026 · DOI 10.1038/s43018-026-01124-3

See every Nature Cancer article on DeepDyve

Questions about Nature Cancer

How can I read Nature Cancer articles without a subscription?

26% of Nature Cancer articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central. Your library may also subscribe. DeepDyve lets you read Nature Cancer articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Nature Cancer?

Nature Cancer’s NLM (PubMed) abbreviation is Nat Cancer.

What is the ISSN of Nature Cancer?

Nature Cancer is published online only; its ISSN is 2662-1347.

Is Nature Cancer open access?

Nature Cancer is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 45 of 172 Nature Cancer articles (26%) carry a Creative Commons license, per Crossref.

What is the impact factor of Nature Cancer?

Nature Cancer’s Journal Impact Factor is 28.0 (2025), and its 5-year Impact Factor is 31.2, according to Springer Nature’s published metrics.

Nature Cancer articles on DeepDyve are licensed from Springer Nature. Journal facts as of 20 November 2026.

Start reading Nature Cancer today

One month free, then less than $2 a day. Nature Cancer, plus millions of articles from thousands of journals.

Start free month

Like this: